Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?
Mucormycosis (zygomycosis) is an uncommon infection that afflicts severely immunocompromised patients and those with poorly controlled diabetes mellitus. A recent increase in the incidence of mucormycosis at many transplant centres has been linked to the introduction and widespread use of voriconazole prophylaxis in these high-risk populations. However, it is not known if this association reflects a true epidemiological link or represents a marker of changing immunosuppression occurring in parallel with the evolution of transplant practices and immunosuppression strategies.
Pongas
G N
GN
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.
Lewis
R E
RE
Samonis
G
G
Kontoyiannis
D P
DP
D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018890:Chemoprevention / Q000379:methods*; D025141:Drug Resistance, Fungal; D006801:Humans; D016867:Immunocompromised Host; D009090:Mucorales / Q000187:drug effects*; D009091:Mucormycosis / Q000209:etiology*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D014180:Transplantation; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole